AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jun 1, 2023
33483_dirs_2023-06-01_70811345-9229-4b74-89ab-32d42ca352fc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-05-30
Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-30 | Common Stock | G | 43000 | — | Disposed | 321316 | Direct |
| 2023-05-30 | Common Stock | G | 43000 | — | Disposed | 278316 | Direct |
| 2023-05-31 | Common Stock | G | 26500 | — | Disposed | 251816 | Direct |
| 2023-05-31 | Common Stock | G | 26500 | — | Disposed | 225316 | Direct |
Footnotes
F1: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid.
F2: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid.
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8